May 24, 2016
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
Key Points
Key points are not available for this paper at this time.
Abstract
These final results from the DASISION trial continue to support dasatinib 100 mg once daily as a safe and effective first-line therapy for the long-term treatment of CML-CP.
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
Jorge E. Cortés
Augusta University Health
G
Giuseppe Saglio
Università Cattolica del Sacro Cuore
Hagop M. Kantarjian
The University of Texas MD Anderson Cancer Center
Journals
Journal of Clinical Oncology
Actions
Institutions
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...